CALQUENCE (acalabrutinib capsules) Patient Assistance Program
Don’t let the high cost of brand second-generation BTK inhibitor disrupt your CLL or mantle cell lymphoma treatment. We help eligible patients access Calquence (acalabrutinib capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Calquence (acalabrutinib) is FDA-approved for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (after ≥1 prior therapy). Second-generation Bruton tyrosine kinase (BTK) inhibitor — more selective for BTK than first-in-class ibrutinib (Imbruvica), with reduced off-target kinase effects, fewer cardiovascular and bleeding side effects, and lower rates of atrial fibrillation.
- Without assistance, Calquence costs commonly run approximately $14,000–$17,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Calquence for a flat $69.95 per month.
- Other BTK inhibitors: ibrutinib (Imbruvica — first-in-class, more off-target effects including AFib, HTN, bleeding), zanubrutinib (Brukinsa — also more selective like acalabrutinib, comparable safety profile, head-to-head superiority in CLL trials), pirtobrutinib (Jaypirca — non-covalent BTKi for ibrutinib-resistant disease). Other CLL/MCL therapies: venetoclax (Venclexta — BCL-2 inhibitor, often combined or sequenced with BTKi), CD20 monoclonals (rituximab biosimilars, obinutuzumab, ofatumumab), PI3K inhibitors (idelalisib, duvelisib — less used due to toxicity), chemoimmunotherapy (FCR, BR — generic chemo backbones with rituximab biosimilar), CAR-T cell therapy (lisocabtagene, brexucabtagene), allogeneic SCT for select cases.
What is Calquence Prescription Assistance Program?
The Calquence Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Calquence (used for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology/oncology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing a hematologic malignancy.
At AffordMyPrescriptions, our Patient Advocates handle the entire Calquence PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, monitor for periprocedural management around any planned procedures, and handle annual re-certification — so you never face a gap in your Calquence BTK inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Calquence enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your CLL or mantle cell lymphoma treatment.
Pharmacy Price Comparison
- Without assistance, Calquence costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this oral targeted therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Calquence advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$16,500/mo | Save substantially |
| CVS Pharmacy | ~$17,000/mo | Save substantially |
| Walmart | ~$14,500/mo | Save substantially |
| Specialty pharmacy | ~$14,000/mo | Save substantially |
| Imbruvica (alt BTKi) | ~$15,000/mo | Alt BTKi — more side effects |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Calquence — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Calquence Prescription Program?
The Calquence Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Calquence’s improved safety profile vs ibrutinib makes it preferred for patients with cardiac risk factors.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Calquence:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $14,000–$17,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly from the manufacturer
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Calquence assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Calquence Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Calquence:
Calquence is a second-generation BTK inhibitor designed with greater selectivity for BTK than first-in-class ibrutinib (Imbruvica). Reduced off-target kinase activity translates clinically to fewer cases of atrial fibrillation, hypertension, bleeding, and diarrhea — particularly important for older CLL patients with cardiovascular comorbidities. Head-to-head trials demonstrated comparable efficacy with improved safety.
How Calquence Works:
Bruton tyrosine kinase (BTK) is a critical signaling kinase downstream of the B-cell receptor — driving malignant B-cell proliferation and survival in CLL/SLL, mantle cell lymphoma, and other B-cell lymphomas.
Calquence covalently binds BTK at Cys-481 — irreversibly inhibits BTK signaling. Greater selectivity for BTK vs other kinases (EGFR, ITK, TEC) reduces off-target effects compared with ibrutinib. Initial ‘redistribution lymphocytosis’ (CLL cells moving from lymph nodes to blood) is expected and not progression. Twice-daily oral dosing offers steady-state exposure.
Form and Use:
Calquence 100 mg capsules. CLL/SLL: 100 mg twice daily (approximately every 12 hours). Mantle cell lymphoma: 100 mg twice daily. Tablet formulation (Calquence Maleate tablets) allows co-administration with proton pump inhibitors. Take with or without food. Continue until disease progression or unacceptable toxicity. Hold for 3–7 days before and after major surgery; manage bleeding risk perioperatively. Avoid grapefruit and Seville oranges (CYP3A4 effects).
Generic Availability:
No generic Calquence. Other BTK inhibitors (all brand): ibrutinib (Imbruvica — first-in-class, more off-target effects, more AFib/HTN/bleeding), zanubrutinib (Brukinsa — also selective, head-to-head superiority over ibrutinib in CLL trials), pirtobrutinib (Jaypirca — non-covalent BTKi for ibrutinib-resistant disease or BTK C481S mutation). Other CLL/MCL therapies: venetoclax (Venclexta — BCL-2 inhibitor, often combined or sequenced with BTKi), obinutuzumab + venetoclax (commonly used CLL frontline non-BTKi option), CD20 monoclonals (rituximab biosimilars Truxima, Ruxience, Riabni; obinutuzumab Gazyva; ofatumumab Arzerra), chemoimmunotherapy (FCR — fludarabine/cyclophosphamide/rituximab biosimilar, BR — bendamustine/rituximab biosimilar), PI3K inhibitors (idelalisib, duvelisib — less used due to toxicity), CAR-T cell therapy (lisocabtagene maraleucel/Breyanzi for CLL after BTKi and venetoclax, brexucabtagene autoleucel/Tecartus for MCL), allogeneic SCT for select fit patients. MCL-specific: bortezomib (generic now), lenalidomide (Revlimid generic now).
Warnings:
**Class concerns: serious infections (bacterial, viral, fungal, opportunistic — HBV reactivation possible), hemorrhage (major bleeding — hold 3–7 days perioperatively, caution with antiplatelets and anticoagulants), cytopenias (neutropenia, thrombocytopenia, anemia — monitor CBC), second primary malignancies (skin cancer especially — sun protection), atrial fibrillation/flutter (less than ibrutinib but still possible), cardiac arrhythmias including ventricular arrhythmias.** Tumor lysis syndrome (high disease burden — monitor labs), embryo-fetal toxicity, headache, diarrhea, musculoskeletal pain, rash, fatigue. Drug interactions: avoid strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit, Seville oranges) — reduce dose; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) contraindicated. PPIs reduce capsule absorption — use Calquence Maleate tablets if PPI co-administration needed.
FAQ (Frequently Asked Questions)
How Much Does Calquence Cost Without Insurance?
$14,000–$17,000 per month. Annual cost approaches $200,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this therapy.
Is Calquence considered chemotherapy?
No — Calquence is a targeted oral therapy (a kinase inhibitor) — not chemotherapy. Different toxicity profile from cytotoxic chemotherapy.
What is the difference between Calquence, Imbruvica, and Brukinsa?
All three are BTK inhibitors for CLL and various B-cell lymphomas. Ibrutinib (Imbruvica) is first-in-class — more off-target kinase effects, more atrial fibrillation, hypertension, bleeding, and diarrhea. Calquence (acalabrutinib) and Brukinsa (zanubrutinib) are second-generation, more selective for BTK — better tolerability, especially cardiac. Both Calquence and Brukinsa have demonstrated superiority over ibrutinib in head-to-head CLL trials. Pirtobrutinib (Jaypirca) is non-covalent — reserved for ibrutinib-resistant disease.
Why does my lymphocyte count rise after starting Calquence?
Expected and not progression — Calquence redistributes CLL cells from lymph nodes and tissues into the bloodstream. This ‘redistribution lymphocytosis’ typically peaks within weeks and gradually resolves over months as the cells die. Lymph nodes shrink simultaneously.
Why are atrial fibrillation and bleeding risks lower with Calquence than Imbruvica?
Calquence is more selective for BTK and has less activity against other kinases involved in cardiac and platelet function. Real-world experience confirms lower rates of AFib, HTN, and major bleeding vs ibrutinib — important for older CLL patients with cardiovascular comorbidities.
What are the major Calquence drug interactions I should know about?
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit, Seville oranges) increase Calquence levels — reduce dose. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid. PPIs reduce capsule absorption — use Calquence Maleate tablets if PPI co-administration is needed.
Can I get live vaccines while taking Calquence?
Avoid live vaccines during therapy. Update non-live vaccines (recombinant zoster, inactivated flu, pneumococcal, COVID-19) before starting or during therapy as appropriate.
What happens if my Calquence Patient Assistance Program application is denied?
We help explore Brukinsa (zanubrutinib — alternative selective BTKi) copay programs, Imbruvica (ibrutinib) assistance, Venclexta (venetoclax) for non-BTKi regimens, Leukemia & Lymphoma Society copay assistance, CancerCare, Patient Access Network, Patient Advocate Foundation, NeedyMeds, Medicare Part D Extra Help and state SPAP programs, and CAR-T center evaluation for appropriate patients.
Take Control of Your Medication Costs
Targeted CLL and mantle cell lymphoma therapy should not be derailed by cost. Calquence’s improved safety profile makes it a preferred BTKi for many patients with cardiovascular risk. Our Calquence advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Calquence through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.